… We reviewed the current evidence for an impact of osteoporosis … for osteoporosis, notably
sclerostin antibody and DKK1 antibody. There is currently no evidence that osteoporosis …

… between primary and secondary osteoporosis because the anti-… causing osteoporosis is
not treated too. In hospital, during the acute phase, it is important to investigate the osteoporosis …

… Osteoporosis is an enormous and growing public health … the evolution of drug therapy for
osteoporosis, which began in the … We note a watershed in osteoporosis drug discovery around …

… Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of
… cost of managing osteoporosis and the cost of QALYs lost, the expenditure of osteoporosis …

… Considerable progress has been made in the development and testing of agents to treat
osteoporosis. Most impressive are reports on new antiresorptive agents—both …

… Thus, increased awareness about how to treat osteoporosis is critical to change the practice
of … options and promising new therapies for the prevention and treatment of osteoporosis. …

… As in women, osteoporosis is a major health and societal … are screened and treated for
osteoporosis and fracture prevention, … for osteoporosis in men as well as insights into new and …

… Osteoporosis is a worldwide health problem with a high prevalence. Agents for the treatment
of osteoporosis are classified as either antiresorptive or anabolic. Antiresorptive agents …

… activator of nuclear factor (NF)-κB ligand (RANKL) and Wnt signaling pathways, and
these pathways are exploited in the development of new therapies for osteoporosis. Citation5 …

… mechanisms and clinical implications of osteoporosis have identified novel therapeutic … for
osteoporosis management in the future. Here, we review the etiology of osteoporosis and the …